Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02693990 · ClinicalTrials.gov registry record · NA

A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas

A NA study of Brain Tumor and Meningioma, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
21
Enrollment target
2
Study locations

NCT02693990 is a NA study of Brain Tumor and Meningioma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 21 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02693990, a NA study of Brain Tumor and Meningioma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
2
Study locations

Study Summary

This research study is studying radiation therapy as a possible treatment for meningioma or tumor on the lining of the brain. The study drug or intervention involved in this research study is Intensity Modulated Proton Therapy (IMPT)

Conditions Studied

Interventions

  • RADIATION Intensity Modulated Proton Therapy (IMPT)

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2016-02
Est. Completion 2027-08
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02693990

The ClinicalTrials.gov registry entry for NCT02693990 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (93% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which Intensity Modulated Proton Therapy (IMPT) is the first listed.

NCT02693990 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT02693990 about?

NCT02693990 is a clinical study titled "A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas". This research study is studying radiation therapy as a possible treatment for meningioma or tumor on the lining of the brain. The study drug or intervention involved in this research study is Intensity Modulated Proton Therapy (IMPT)

What is the current status of trial NCT02693990?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2016-02. Estimated completion is 2027-08.

What conditions does trial NCT02693990 study?

This clinical trial studies the following conditions: Brain Tumor, Meningioma.

What interventions are being tested in trial NCT02693990?

The interventions under investigation include: Intensity Modulated Proton Therapy (IMPT) (RADIATION).

Who is sponsoring clinical trial NCT02693990?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02693990 being conducted?

This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.